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E D I T O R I A L
Papa Giovanni XXIII Bergamo Hospital at the time of the 
COVID-19 outbreak: Letter from the warfront…
1  | INTRODUC TION
In early December 2019, the 2019 novel coronavirus (COVID-19) was 
identified as the agent responsible for the first pneumonia cases of 
unknown origin in Wuhan, the capital of the Hubei region in China. 
The virus has been identified as a novel enveloped RNA betacorona-
virus 2, that has been promptly named SARS-CoV-2 (severe acute re-
spiratory syndrome coronavirus 2). The World Health Organization 
(WHO), on January 12, 2020, declared the COVID-19 a public health 
emergency of international concern. On March 11, the WHO made 
the assessment that COVID-19 can be characterized as a pandemic.
The COVID-19 infection, documented both in hospitals and in 
home settings, has spread diffusely worldwide with local minor dif-
ferences, totaling over 234 073 laboratory-confirmed cases as of 
March 19, 2020.1
The first documented case in Italy was identified in a 38-year-old 
manager in the province of Lodi, Lombardy, in the north of Italy. The 
first documented case in our hospital (Bergamo Province, of over 
1.1 million inhabitants) was identified on Friday, February 21, 2020.
In this report, we describe the call for action activated to tackle 
the epidemic. The rapid increase of positive cases has caused, on 
the one hand, widespread panic among the people and on the other 
hand, the need for profound structural and logistical reorganizations 
of the Papa Giovanni XXIII Hospital. In this context, we describe the 
role of the laboratory.
Starting from Saturday February 22, half of the infectious dis-
ease ward was dedicated to COVID-19 patients, moving 24 non-
COVID-19 patients to other medical units of the same hospital or 
discharging them. On February 23, it became clear that this conver-
sion was not enough and by Friday February 28, all of the 48 beds of 
the infectious disease unit were occupied. From that day on, every 
48 hours, a new 48-bed unit was prepared, transferring out of the 
hospital the non-COVID-19 patients. In a rapid and tremendously or-
ganized fashion, several medical and surgical units were dismantled 
to create dedicated COVID-19 units, rapidly occupied by patients 
undergoing respiratory support (mainly continuous positive airway 
pressure, CPAP), up to 140 devices working simultaneously and 
some bi-level noninvasive ventilation, (NIV). As of March 10, 2020, 
five COVID-19-dedicated units (48 beds each) were progressively 
activated moving non-COVID-19-related patients to either other de-
partments, external hospitals, or discharged. More than 35% of the 
medical personnel (approximately 400 physicians of any discipline), 
together with over 900 nurses, have been recruited and specifically 
formed to be fully dedicated to the newly born COVID-19 units. As 
of today, we are activating the sixth 48-bed unit. An additional 45 
beds were prepared in San Giovanni Bianco Hospital (a section of 
our hospital, a few miles away from the main location).
Simultaneously, the hospital increased the number of insensitive 
care unit (ICU) beds from the initially dedicated 8-bed unit to the 
current number of 88 ICU beds plus 12 respiratory semi-intensive 
unit beds.
On an average day, as of February between 80 and 90 patients 
are attended in the emergency room (ER), distributed as follows:
• 5%-10% in the shock room (for intubated or in CPAP patients)
• 25% in the emergency medicine unit (up to 24 patients on CPAP/
NIV)
• Over 60% in the atrium (up to 50 patients, 50% on oxygen 
supplementation)
The rapid spread of the infection has led to a progressive in-
crease in the number patients of accessing to the ER.
In this context, the hematology laboratory has seen a progres-
sive reduction of tests required for outpatients versus inpatients due 
to COVID-19.
The laboratory plays an essential role in the diagnosis, even 
early, in the management, follow-up, and in the prognosis of many 
diseases.2
The diagnosis and the management of patients with COVID-19 
are no exception to this paradigm; indeed, the molecular diagnostics 
testing allows for the direct identification of RNA virus, while the 
detection of specific antibodies for COVID-19 is the cornerstone for 
serological surveillance.
The increase of critically ill patients has put the ICUs to the 
test. Therefore, there is an urgent need to identify the clinical and 
laboratory predictors which allow for risk assessment, the most 
appropriate clinical pathways, and the optimization of resource 
allocation.
Currently, the clinical characteristics of patients with COVID-19 
are well described,3-5 while few and contradictory information are 
available on the laboratory tests6 such as the complete blood count 
(CBC) parameters.7-10 Data on the most innovative parameters of 
the CBC profile (CBC extended) (ie, immature granulocytes, reac-
tive lymphocytes and the nucleated red cells automatic counts, the 
platelet fraction or reticulated platelets, the erythrocyte and reticu-
locyte indices), are not currently available in literature.
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The only published and studied data on CBC parameters are fo-
cused on small case series which often do not exceed more than 100 
subjects and are able to show that absolute lymphopenia is predic-
tive of an increased risk of complications in ICU patients.8,9
As a matter of fact, the evidence on all other CBC parameters 
shows contradictory results, perhaps due to timing in which the 
test is performed with respect to the development of the disease 
and factors such as ethnicity, gender, age, comorbidity, and possible 
therapeutic treatments. A puzzling factor lies adequate, but differ-
ent multivariate statistical analyses that have been used in published 
articles. Nevertheless, we have no choice but to use whatever infor-
mation is available.
On a cohort of 300 COVID-19 patients randomly selected from 
those evaluated in the ER in the first week of the Bergamo outbreak, 
the lymphopenia was observed, but not anemia or thrombocytope-
nia. The leukocyte counts were normal, and only about 1% of sub-
jects was observed to have the presence of circulating erythroblasts 
(ie, 0.02 × 109/L). Manual microscopy review showed the presence 
of reactive lymphocytes of which a subset appeared lymphoplasma-
cytoid according to Fan et al9
These are, of course, preliminary data of a timely observation 
from which no conclusions or indications can be drawn. These data 
must be supplemented with clinical information for the correct mul-
tivariate statistical analyses to be done.
With regard to the safety of laboratory staff manipulating pe-
ripheral blood samples, a recent study by Wang et al11 showed that 
a small percentage of blood samples had positive reverse transcrip-
tase-polymerase chain reaction (RT-PCR) test results (ie, 1%), sug-
gesting that infection sometimes may be systemic, this study does 
not address the viability of the virus. The presence of viral RNA in 
the peripheral blood does not imply that infection may be transmit-
ted by the parenteral route. Aerial transmission is considered the 
major exposure risk for coronaviruses such as SARS-CoV-2.
The WHO released documents to provide interim guideline for 
the management of samples that might contain SARS-CoV-2.12
Iwen et al13 in a recent article points out that MERS-CoV and 
SARS-CoV cases as a laboratory-acquired infections are very rare 
and caused by incorrect safety behaviors of laboratory staff.
The level of biosafety for virology labs depends on the type of 
activity performed. Biosafety level 2 or level 3 hoods are used for 
nonpropagative and propagative work of diagnostic laboratory, re-
spectively.12 While a precise indication for all other laboratories at 
the moment is not available, the hematology laboratory staff must 
follow the rules of the biosafety and regulatory standards provided, 
according to the local risk assessment.13
Despite the emergency and limited time availability, more infor-
mation is needed about the actual CBC pattern of COVID-19-positive 
subjects at different stages of disease development, for proper risk 
stratification, appropriateness of hospitalization and monitoring. 
Only this way, will it be possible to identify which, among the many 
parameters of the CBC extended profile, may have a real predictive 
value for the clinical progression and risk of complications of acute 
lung damage/acute respiratory distress syndrome.
Only the proper production of strong scientific evidence can 
avoid the risk of interpretative errors, leading to potential delays in 
identifying the best therapeutic strategies.
It should also be considered that the preparation of Papa 
Giovanni XXIII Hospital as the COVID-19 Hospital in Bergamo, 
with the total closure of health care, except for emergencies and 
oncological patients, will eventually lead to a delayed diagnosis of 
a great number of pathologic conditions, especially in hematology 
and oncology patients. There will be a progressive complexity of the 
cases which will gradually be diagnosed and require more attention 
and care from clinicians and many other resources to prevent worse 
outcomes.
In the claim of great technological development and rapid sharing 
of information, it is necessary to enhance national and international 
cooperation and networks for sharing data and big data technologies 
from a multidisciplinary perspective.
In these days, humanity is facing a long fraught road with obsta-
cles, with an unknown destination. In this situation, time factor is the 
key factor in order to save as many lives as possible. Time is critical.
The lessons learned that should be shared with both health per-
sonnel and the general population:
• We were forced to mobilize a whole hospital (a 1000-bed hospi-
tal) for COVID-19 patient.
• There is no need to panic, or to rush to somewhere. Just stay 
home, and reinforce hand hygiene (if no alcoholic solution is avail-
able, 40-60 seconds of washing with soap and water is enough).
• Dutifully comply with the institutional indications for avoiding 
close contact and large gatherings of people (movies, theaters, 
sports events, schools, universities, meeting, and similar should be 
avoided).
• Strictly adhere to the antispread protection rules when in close 
contact with an infected or possibly infected individual.
• If you are infected (or a close contact is infected) and asymptom-
atic, please DO RESPECT the quarantine for at least 14 days. Do 
not go to the ER or take public transportation. If you are symp-
tomatic call, the emergency number provided by your local 
government.
• The main message should be: “I am part of the solution” …. if one 
believes that the problem is upon someone else it shall never work 
(“If we ALL feel involved, together we can beat it”).
• But most of all, if you PREPARE yourself at all levels (population, 
institutions, health workers), you will defend all.
In times of globalization, when the critical phase of this emer-
gency is overcome, a deep reflection on global risk assessment strat-
egies, economic, social development priorities, and development 
policies will be needed. It is also necessary to define and ensure a 
global health care and hygiene is essential at all levels, to warrant 
a health system which is necessarily barrier-free between states. If 
humanity is able to analyze this global crisis in the right perspective, 
maybe we can discover new horizons and new opportunities for a 
better future.
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